237 related articles for article (PubMed ID: 25144285)
1. Metastatic adrenocortical carcinoma with a prolonged response to mitotane.
Pal SK; Gartrell B; Olsson CA; Stein CA
Oncology (Williston Park); 2014 Jul; 28(7):624-5, 642. PubMed ID: 25144285
[No Abstract] [Full Text] [Related]
2. Adjuvant mitotane in adrenocortical carcinoma.
Machens A; Dralle H
N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837
[No Abstract] [Full Text] [Related]
3. Surgical management of adrenocortical carcinoma.
Ranvier GG; Inabnet WB
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
[TBL] [Abstract][Full Text] [Related]
4. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
Demeure MJ; Somberg LB
Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
[TBL] [Abstract][Full Text] [Related]
5. [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
Yamashita D; Hanai T; Onuki T; Suzuki K; Nakayama T
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):12-17. PubMed ID: 31956212
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of adrenocortical carcinoma with pulmonary metastasis in a child: report of a case.
Arai H; Rino Y; Yamanaka S; Yukawa N; Wada N; Kato H; Yanagimachi M; Goto H; Oshiro H; Yamanaka S; Inayama Y; Lee J; Masuda M
Surg Today; 2008; 38(10):965-9. PubMed ID: 18820878
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
8. [Successful surgical treatment of adrenal cancer with repeated metastasis].
Paliutko IuI; Gakhramanov AD
Khirurgiia (Mosk); 2008; (12):51-3. PubMed ID: 19938263
[No Abstract] [Full Text] [Related]
9. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
Dickstein G; Shechner C; Arad E; Best LA; Nativ O
J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment for adrenocortical carcinoma].
Iihara M; Obara T
Gan To Kagaku Ryoho; 2004 Mar; 31(3):342-5. PubMed ID: 15045937
[TBL] [Abstract][Full Text] [Related]
11. Clinical Score Predicting Overall Survival After Surgery for Synchronous Metastatic Adrenocortical Carcinoma: A Surveillance, Epidemiology, and End Result-Based Study.
Wu K; Liu Z; Li X; Lu Y
Am Surg; 2021 May; 87(5):805-811. PubMed ID: 33228399
[TBL] [Abstract][Full Text] [Related]
12. Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
Beom SH; Lee KW; Yang Y; Choi Y; Song KH; Kim YJ; Kim JH; Bang SM; Chung JH; Lee JS
Jpn J Clin Oncol; 2011 Nov; 41(11):1287-91. PubMed ID: 21980052
[TBL] [Abstract][Full Text] [Related]
13. [Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP'DDD alone].
Remond S; Bardet S; Charbonnel B
Presse Med; 1992 May; 21(18):865. PubMed ID: 1535153
[No Abstract] [Full Text] [Related]
14. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant mitotane in adrenocortical carcinoma.
Dickstein G; Shechner C; Nativ O
N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
[No Abstract] [Full Text] [Related]
16. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
17. Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocrine; 2016 Jun; 52(3):664-7. PubMed ID: 26645813
[No Abstract] [Full Text] [Related]
18. [Histoculture drug response assay guided concurrent chemoradiotherapy for lung metastasis from adrenocortical carcinoma--a case report].
Yoshimasu T; Oura S; Hirai I; Kokawa Y; Nishida M; Sasaki R; Tanino H; Sakurai T; Okamura Y; Inagaki T; Kodama Y; Shinke T
Gan To Kagaku Ryoho; 2004 Mar; 31(3):435-7. PubMed ID: 15045957
[TBL] [Abstract][Full Text] [Related]
19. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
[No Abstract] [Full Text] [Related]
20. Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.
Mayor-Ibarguren A; Roldán-Puchalt MC; Gómez-Fernández C; Albízuri-Prado F; Álvarez-Escola C
JAMA Dermatol; 2016 Jan; 152(1):109-11. PubMed ID: 26444320
[No Abstract] [Full Text] [Related]
[Next] [New Search]
